Antibody-drug conjugates: Current status and future perspectives
1Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 1-5/10, CH 8053, Zurich, Switzerland.
Pharmacology & Therapeutics
|August 6, 2016
Summary
Antibody-drug conjugates (ADCs) offer targeted cancer therapy by delivering potent drugs directly to tumors, improving efficacy and reducing side effects. Advances in payloads, linkers, and targets enhance ADC development for better cancer treatment outcomes.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Conventional chemotherapy lacks tumor selectivity, limiting efficacy and causing systemic toxicity.
- Monoclonal antibodies offer a targeted approach for drug delivery to neoplastic lesions.
- Antibody-drug conjugates (ADCs) represent a promising class of targeted biopharmaceuticals.
Purpose of the Study:
- To review advancements in antibody-drug conjugate (ADC) technology.
- To summarize pre-clinical and clinical examples of ADC improvements.
- To discuss combination therapies involving ADCs and checkpoint inhibitors.
Main Methods:
- Review of pre-clinical and clinical studies on ADCs.
- Analysis of diversification in payloads, linkers, conjugation technologies, ADC formats, and targets.
- Discussion of combination therapies with checkpoint inhibitors.
Main Results:
- Significant improvements in ADC technology have been observed.
- Diversification in payloads, linkers, conjugation methods, formats, and targets enhances ADC capabilities.
- Combination therapies of ADCs with checkpoint inhibitors show promising potential.
Conclusions:
- ADCs demonstrate potential for improved anti-cancer activity and selectivity.
- Ongoing technical advancements are crucial for successful ADC development.
- Combination strategies, particularly with checkpoint inhibitors, warrant further investigation for enhanced cancer treatment.
More Related Videos
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
8.3K
09:39Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
7.4K
Related Concept Videos
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:31Hybridoma Technology
18.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.2K
01:14Phase II Conjugation Reactions: Overview
1.1K
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
1.1K
01:16Therapeutic Drug Monitoring: Overview and Classification
487
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
487
01:26Antibody Actions
3.4K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.4K
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
82
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
82